Literature DB >> 11996792

Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls.

Steve S Sommer1, Carolyn H Buzin, Mira Jung, Jian Zheng, Qiang Liu, Sook J Jeong, Jefferson Moulds, Vu Q Nguyen, Jinong Feng, William P Bennett, Anatoly Dritschilo.   

Abstract

Studies of families of patients with ataxia telangiectasia (A-T) show an increased risk of breast cancer in heterozygous A-T carriers. However, expected increased levels of mutations in the ATM gene among unselected breast cancer patients have not been found to date. Previous methods of mutation detection were biased toward the detection of truncating mutations, and single nucleotide substitutions were likely to have been underreported. In this study, genomic DNA from 43 breast cancer patients and 43 control individuals were scanned for mutations in the entire ATM coding region (exons 4-65) and adjacent intronic splice regions (three megabases total) using detection of virtually all mutation-single-strand conformation polymorphism (SSCP), a modification of SSCP with sufficient redundancy to detect virtually all mutations. Excluding a polymorphism found commonly in cases and controls, there were missense changes in 12 breast cancer patients, one of whom also had a protein truncating mutation, versus six controls (P=0.09). When all structural changes common to the cases and controls were excluded, missense or truncating changes were found in 10 cases compared to two in controls (P=0.013). The background of missense changes in controls is high. There is a trend towards elevation of all structural changes in cases, but the results are not statistically significant. Cohort-specific structural changes are significantly more prevalent in the breast cancer patients. The data are compatible with certain missense mutations in ATM predisposing to breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996792     DOI: 10.1016/s0165-4608(01)00594-5

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  13 in total

1.  Functional variations in the ATM gene and susceptibility to differentiated thyroid carcinoma.

Authors:  Li Xu; Elaine Cristina Morari; Qingyi Wei; Erich M Sturgis; Laura S Ward
Journal:  J Clin Endocrinol Metab       Date:  2012-03-21       Impact factor: 5.958

2.  New mutations in the ATM gene and clinical data of 25 AT patients.

Authors:  Ilja Demuth; Véronique Dutrannoy; Wilson Marques; Heidemarie Neitzel; Detlev Schindler; Petja S Dimova; Krystyna H Chrzanowska; Veneta Bojinova; Hanna Gregorek; Luitgard M Graul-Neumann; Arpad von Moers; Ilka Schulze; Marion Nicke; Elcin Bora; Tufan Cankaya; Éva Oláh; Csongor Kiss; Beáta Bessenyei; Katalin Szakszon; Ursula Gruber-Sedlmayr; Peter Michael Kroisel; Sigrun Sodia; Timm O Goecke; Thilo Dörk; Martin Digweed; Karl Sperling; Joaquim de Sá; Charles Marques Lourenco; Raymonda Varon
Journal:  Neurogenetics       Date:  2011-10-02       Impact factor: 2.660

3.  ATM haplotypes and associated mutations in Iranian patients with ataxia-telangiectasia: recurring homozygosity without a founder haplotype.

Authors:  Mahnoush Babaei; Midori Mitui; Eric R Olson; Richard A Gatti
Journal:  Hum Genet       Date:  2005-04-21       Impact factor: 4.132

Review 4.  ATM and genome maintenance: defining its role in breast cancer susceptibility.

Authors:  Kum Kum Khanna; Georgia Chenevix-Trench
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

5.  The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.

Authors:  Denise L Stredrick; Montserrat Garcia-Closas; Marbin A Pineda; Parveen Bhatti; Bruce H Alexander; Michele M Doody; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Stephen J Chanock; Jeffery P Struewing; Alice J Sigurdson
Journal:  Hum Mutat       Date:  2006-06       Impact factor: 4.878

6.  Immunodeficiency, radiosensitivity, and the XCIND syndrome.

Authors:  Richard A Gatti; Elena Boder; Robert A Good
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

7.  No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer.

Authors:  Amanda B Spurdle; John L Hopper; Xiaoqing Chen; Margaret R E McCredie; Graham G Giles; Beth Newman; Georgia Chenevix-Trench; KumKum Khanna
Journal:  Breast Cancer Res       Date:  2002-08-21       Impact factor: 6.466

8.  Gene-environment interaction for polymorphisms in ataxia telangiectasia-mutated gene and radiation exposure in carcinogenesis: results from two literature-based meta-analyses of 27120 participants.

Authors:  Yuguang Zhao; Lei Yang; Di Wu; Hua He; Mengmeng Wang; Tingwen Ge; Yudi Liu; Huimin Tian; Jiuwei Cui; Lin Jia; Ziqiang Wan; Fujun Han
Journal:  Oncotarget       Date:  2016-11-22

9.  Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.

Authors:  Geoffrey J Lindeman; Melody Hiew; Jane E Visvader; Jennifer Leary; Michael Field; Clara L Gaff; R J McKinlay Gardner; Kevin Trainor; Glenice Cheetham; Graeme Suthers; Judy Kirk
Journal:  Breast Cancer Res       Date:  2004-06-02       Impact factor: 6.466

10.  ATM polymorphisms as risk factors for prostate cancer development.

Authors:  S Angèle; A Falconer; S M Edwards; T Dörk; M Bremer; N Moullan; B Chapot; K Muir; R Houlston; A R Norman; S Bullock; Q Hope; J Meitz; D Dearnaley; A Dowe; C Southgate; A Ardern-Jones; D F Easton; R A Eeles; J Hall
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.